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Absolute pitch (AP) is the term used to denote the cognitive
ability to spontaneously and effortlessly identify and vocally
produce speciﬁc musical tones without a reference note.1
Abnormalities of pitch perception are a recognized rare side effect
of carbamazepine (CBZ). The mechanism of this side effect is not
clear. The same symptom may also be associated with oxcarba-
zepine (OXC) although this is even rarer. We report a twenty-two
year-old woman with partial and prolonged secondarily general-
ized seizures who complained of a one semitone lowering of pitch
perception during CBZ therapy. After stopping CBZ and switching
to OXC, she noticed that pitch perception was one semitone higher
than normal.
2. Case report
A twenty-two year-old right handed English woman had been
followed up in outpatients since the age of thirteen, with the
diagnosis of symptomatic focal epilepsy with complex partial and
prolonged secondarily generalized seizures. MRI brain showed
bilateral periventricular nodular heterotopia thought to be the
etiology of her epilepsy. She was also known to have autoimmune* Corresponding author at: Kozmoklinik Muzeyyen Sok, No: 1, 34740 Suadiye,
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epilepsy and her neurological examination was unremarkable.
Lamotrigine, topiramate and levetiracetam were tried as mono-
therapies and were discontinued because of side effects and
inadequate seizure control. CBZ which had not been used as a ﬁrst-
line therapy to avoid worsening of hypothyroidism, was used after
the aforementioned drugs and had been both the most effective
and the best tolerated agent. The patient was a keen pianist and
cellist and had AP. She was hoping to embark upon a career as a
professional musician. She was able to identify any given musical
note without an external reference. She noted, during review, that
she had experienced a global down-shift of pitch by one semitone.
This initially occurred after dose changes only and remitted within
a few weeks while continuing CBZ. CBZ was increased up to 600 mg
bd but higher dose did not impact on seizure control and more side
effects in particular increased tiredness developed. CBZ was
stopped and after switching to OXC she again noticed altered
pitch perception. The switch was performed directly from one drug
to the other. She noticed that pitch seemed one semitone higher
than normal. Again this occurred after dose increases only and
lasted for about one week before remitting whilst continuing OXC.
On OXC 450 mg mornings and 600 mg evenings, she suffered ﬁve
partial seizures a month. Lacosamide (LCM) was added and
gradually increased to 250 mg bd. She did not have any change in
pitch perception whilst on LCM.
3. Discussion
CBZ is a ﬁrst-line anti-epileptic drug in partial and generalized
seizures which is also indicated in trigeminal neuralgia and various
affective disorders. Its major side effects are dizziness, sleepiness
and cerebellar symptoms.2 Auditory disturbances are a rare side-
effect. Twenty-six cases of pitch-shift following CBZ administra-
tion have been reported.3 Twenty-ﬁve of the reported cases were
Japanese. The reported problem was mainly lowered pitch but two
of the cases were said to have experienced higher pitch. AP is a
term which denotes the cognitive auditory ability to spontaneous-
ly and effortlessly identify and vocally produce speciﬁc musical
tones without a reference note.1 In other words recognizing AP is
the ability to immediately attach the sound name ‘‘do’’, ‘‘re’’, ‘‘mi’’
to the heard sound and sing the appropriate note on hearing the
sound name.4 Data suggest a notably higher prevalence of AP in
Asians compared to other ethnic groups in various music
programs. Overall 32.1 percent of Asians had AP versus 7 percentvier Ltd. All rights reserved.
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is linked to the variations in the frequency and nature of musical
training in early childhood in these populations.6 In addition to
hereditary factors, training from childhood is necessary, but not
sufﬁcient, for the acquisition of the AP.4
Abnormalities of pitch perception are a recognized side effect of
CBZ. Whilst rarely reported, it is possible that the effect itself is a
common side effect with but it is only recognized in those patients,
usually highly musically trained, who are able to articulate this
subtle symptom. The mechanism of this effect is not clear. There
are several indications that CBZ affects the auditory system. De la
Cruz and Bance reported a case of attempted suicide in which the
patient had taken 36 g CBZ and complained of reversible hearing
loss and tinnitus.7 The brainstem auditory-evoked response of a
patient who experienced auditory disturbance with CBZ was found
to be normal7 suggesting that the hearing conduction pathway was
not impaired. Various mechanisms have been posited to explain
this phenomenon, including impairment at the recognition level8 a
disorder of perception affecting the limbic system9 or affecting the
outer hair cells of the organ of Corti.10 A detailed recent analysis of
CBZ-induced pitch shift in a concert pianist suggested that the drug
probably shifts frequency ﬁltering likely at brainstem level,
without affecting tone-scale representation in higher centres.
Given the lack of impact on musical timbre an impact at the
cochlear level was felt unlikely.11
There are many reported cases of CBZ-induced reversible pitch
change but, as far as we know, pitch change in patients with AP
whilst on OXC has not been reported previously in the literature.
The occurrence of this side effect is likely to be explained by the
similar mode of action of both drugs. It is notable that our patient
did not report any pitch shift with LCM.
The primary mechanism of action of CBZ and OXC is use-
dependent blockade of voltage-dependent sodium channels. Given
the tendency to develop pitch-related adverse effects with both
CBZ and OXC it could be inferred that sodium channels may be
involved in the physiology of AP. Lacosamide, which was tolerated
without any change of pitch, is also a sodium channel blocker but
with a slightly different mode of action.12 LCM inactivates the slow
sodium channels whereas CBZ and OXC inactivate the fast sodium
channels. This difference may be responsible for the lack of pitch-
related side effects associated with LCM in this patient.In summary, we have described for the ﬁrst time the adverse
effect of a one semitone sharpening of pitch with OXC in a patient
with AP, who had one semitone ﬂattening of pitch with CBZ and no
change of pitch perception with LCM. This may help raise
awareness of this side effect and contribute further to the
understanding of pathophysiology of AP.
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